AU4577899A - Hla binding peptides and their uses - Google Patents

Hla binding peptides and their uses

Info

Publication number
AU4577899A
AU4577899A AU45778/99A AU4577899A AU4577899A AU 4577899 A AU4577899 A AU 4577899A AU 45778/99 A AU45778/99 A AU 45778/99A AU 4577899 A AU4577899 A AU 4577899A AU 4577899 A AU4577899 A AU 4577899A
Authority
AU
Australia
Prior art keywords
binding peptides
peptides
hla binding
immunogenic
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45778/99A
Other languages
English (en)
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of AU4577899A publication Critical patent/AU4577899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU45778/99A 1998-06-17 1999-06-17 Hla binding peptides and their uses Abandoned AU4577899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9858498A 1998-06-17 1998-06-17
US09098584 1998-06-17
PCT/US1999/013789 WO1999065522A1 (en) 1998-06-17 1999-06-17 Hla binding peptides and their uses

Publications (1)

Publication Number Publication Date
AU4577899A true AU4577899A (en) 2000-01-05

Family

ID=22269985

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45778/99A Abandoned AU4577899A (en) 1998-06-17 1999-06-17 Hla binding peptides and their uses

Country Status (8)

Country Link
EP (2) EP1089757B1 (enExample)
JP (2) JP2002518346A (enExample)
AT (1) ATE429247T1 (enExample)
AU (1) AU4577899A (enExample)
CA (1) CA2330824A1 (enExample)
DE (1) DE69940774D1 (enExample)
ES (1) ES2326146T3 (enExample)
WO (1) WO1999065522A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
EP1237564A4 (en) * 1999-12-10 2005-05-04 Epimmune Inc TRIGGERING OF CELLULAR IMMUNE RESPONSES AGAINST P53 USING NUCLEIC ACID AND PEPTIDE COMPOSITIONS
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1766393A4 (en) * 2004-05-07 2008-06-18 Beckman Coulter Inc MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA2919835A1 (en) 2013-07-31 2015-02-05 Board Of Trustees Of The University Of Arkansas Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69031305T2 (de) 1989-11-03 1998-03-26 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
ATE342730T1 (de) * 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
JPH10510988A (ja) * 1994-12-14 1998-10-27 ザ スクリップス リサーチ インスティテュート 腫瘍−特異的細胞毒性ｔ細胞のインビボ活性化
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
DK0900380T3 (da) * 1996-04-26 2003-11-03 Seed Capital Investments Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper

Also Published As

Publication number Publication date
EP1089757A4 (en) 2002-10-30
EP1089757B1 (en) 2009-04-22
ES2326146T3 (es) 2009-10-01
ATE429247T1 (de) 2009-05-15
CA2330824A1 (en) 1999-12-23
EP1089757A1 (en) 2001-04-11
EP2036573A1 (en) 2009-03-18
JP2002518346A (ja) 2002-06-25
DE69940774D1 (de) 2009-06-04
WO1999065522A1 (en) 1999-12-23
JP2010090167A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
AU5898400A (en) Hla binding peptides and their uses
AU2001298049A1 (en) Hla class i and ii binding peptides and their uses
AU6597998A (en) HLA-A2.1 binding peptides and their uses
AU6195398A (en) HLA binding peptides and their uses
EP0907370A4 (en) HLA-A2.1 BINDING PEPTIDES AND USES THEREOF
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
NZ506453A (en) Compositions and methods for regulating lymphocyte activation
DK1123086T3 (da) Kunstige antigen-specifikke celler og tilhørende fremgangsmåder
EP1916297A3 (en) Cell separation compositions and methods
AU1552599A (en) Novel peptide, apoep1.b, compositions and uses thereof
AU5963500A (en) Peptides for vaccinating against human cmv
AU4577899A (en) Hla binding peptides and their uses
AU2003213580A1 (en) Subtilisin carlsberg proteins with reduced immunogenicity
WO2004007528A3 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
AU2000273396A1 (en) Hla binding peptides and their uses
WO2001023560A3 (en) Isolated peptides which bind to mhc class ii molecules, and uses thereof
WO1999047102A3 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
WO1999009167A8 (en) Porcine mhc class i genes and uses thereof
WO2004011483A3 (en) Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
WO2004020592A3 (en) Retroductal salivary gland genetic vaccination
WO2000071573A3 (en) Immunogenic peptides derived from mage and the use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase